A new approach to treating heart failure
A novel strategy for heart failure therapeutics
This study is looking at a tiny molecule called miR-128 that seems to be higher in hearts that are not working well, to help us understand how it affects heart muscle cells and find new ways to treat heart failure, which could lead to better options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10997341 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind heart failure, focusing on a specific microRNA (miR-128) that is found to be elevated in failing hearts. By understanding how this microRNA contributes to heart muscle cell changes, the research aims to identify new therapeutic strategies to prevent the progression of heart failure. The study utilizes advanced techniques like next-generation sequencing to explore the genetic factors involved in heart function deterioration. Patients may benefit from insights that could lead to innovative treatments targeting the underlying causes of heart failure.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure or those at risk of developing heart failure due to cardiac dysfunction.
Not a fit: Patients with heart conditions unrelated to heart failure or those who do not have any cardiac issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve heart function and quality of life for patients with heart failure.
How similar studies have performed: Other research has shown promise in targeting microRNAs for heart disease treatment, indicating that this approach could be a viable strategy.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Wang, Yigang — University of Cincinnati
- Study coordinator: Wang, Yigang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.